This page will host Events plug-in for all Clarion and trade events.

Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HeartSciences Inc. - Warrant (NQ:HSCSW)

0.1174 +0.0450 (+62.15%)
Streaming Delayed Price Updated: 1:01 PM EDT, Mar 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 101
Open 0.1174
Bid (Size) 0.0730 (1,000)
Ask (Size) 0.1174 (1,600)
Prev. Close 0.0724
Today's Range 0.1174 - 0.1174
52wk Range 0.0350 - 0.2000
Shares Outstanding 10,362,284
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
From HeartSciences Inc.
Via GlobeNewswire

Performance

YTD
+51.5%
+51.5%
1 Month
+48.4%
+48.4%
3 Month
-8.6%
-8.6%
6 Month
+46.9%
+46.9%
1 Year
+191.3%
+191.3%

More News

Read More
News headline image
University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
From HeartSciences Inc.
Via GlobeNewswire
News headline image
Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Conference Participation and Investor Webinar
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
From HeartSciences Inc.
Via GlobeNewswire
News headline image
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is HeartSciences Inc. - Warrant publicly traded?
Yes, HeartSciences Inc. - Warrant is publicly traded.
What exchange does HeartSciences Inc. - Warrant trade on?
HeartSciences Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for HeartSciences Inc. - Warrant?
The ticker symbol for HeartSciences Inc. - Warrant is HSCSW on the Nasdaq Stock Market
What is the current price of HeartSciences Inc. - Warrant?
The current price of HeartSciences Inc. - Warrant is 0.1174
When was HeartSciences Inc. - Warrant last traded?
The last trade of HeartSciences Inc. - Warrant was at 03/24/26 01:01 PM ET
What is the market capitalization of HeartSciences Inc. - Warrant?
The market capitalization of HeartSciences Inc. - Warrant is 1.22M
How many shares of HeartSciences Inc. - Warrant are outstanding?
HeartSciences Inc. - Warrant has 1M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.